Oak Street Health, Inc.

Q3 2022 reported revenue was $545.7 million, up 40% year over year, and adjusted for prior-period changes total revenue grew 48%. Capitated revenue was $537.9 million, up 43% year over year, or 51% adjusted for prior-period impacts. Medical claims expense was $427.4 million, up 38% year over year, and adjusted for prior-period changes it grew 47%. Adjusted EBITDA was a loss of $88.3 million versus a loss of $64.4 million a year ago. At-risk patients grew 44% to 145,000, and the company operated 161 centers at quarter-end, up 51 centers or 46% from the prior-year period. Patient contribution was $110.5 million, up 65%; platform contribution was $6 million, up 94%. For full-year 2022, management raised at-risk patient guidance to 157,000-159,000, revenue guidance to $2.15 billion-$2.155 billion, kept centers at 169, and narrowed adjusted EBITDA loss guidance to $292.5 million-$287.5 million.

Mike Pykosz emphasized that the quarter reflected strong execution across the company’s care model and patient acquisition engine, calling out results above the top end of guidance for revenue, centers, at-risk patients, and adjusted EBITDA. He repeatedly framed Oak Street’s differentiation as its patient experience, community-based marketing, and better engagement that lowers hospitalization rates and supports stronger economics over time. His tone was confident and upbeat, but he also stressed continued investment in technology, Canopy, RubiconMD integration, and center expansion as part of a long-term scaling plan.

Tim Cook focused on the financial bridge from patient growth to revenue and EBITDA, noting at-risk patients grew 44% to 145,000 and that capitated revenue of $537.9 million grew 43% year over year, or 51% adjusted for prior-period items. He highlighted medical claims expense of $427.4 million, patient contribution of $110.5 million, platform contribution of $6 million, and an adjusted EBITDA loss of $88.3 million. On liquidity and capital allocation, he said Oak Street ended Q3 with about $543 million in unrestricted cash and marketable securities plus $225 million of loan availability, drew $75 million at closing of the new loan, and expects operating cash flow and adjusted EBITDA loss to roughly converge over the year; he also said the company can fund 30-40 new centers in 2023 and 2024 without raising incremental equity capital.

Analysts focused heavily on Direct Contracting retroactive patient adjustments, Q4 utilization and COVID/respiratory illness costs, and whether the new debt signaled a change in capital needs. Tim Cook said the debt deal was mainly prudence and “good corporate housekeeping,” not a change in expectations, and that the company was being proactive about Direct Contracting panel management because CMS can retroactively remove patients. Other questions centered on PACE, the CHW acquisition, the NP fellowship, RubiconMD integration, AEP, and the impact of MA Star changes; management said these were all strategic complements to the core model, with RubiconMD eConsult usage trending up and AARP/AEP viewed as supportive but not the main driver of growth.